In this study the cardioprotective effects of the novel lipophilic iron chelator against chronic anthracycline cardiotoxicity were investigated. Using 10 mg/kg of the chelator administered 30 min before the every daunorubicin dose the significant cardioprotection was obtained (as shown by prevention of cardiac-related deaths, improved functional, biochemical and morphological parameters).
On the other hand escalation of the dose to the 25 mg/kg did not improved cardiovascular parameters, on the contrary, the cardioprotective potential was lost and early extracardiac toxicity was observed.